Onspira Therapeutics

Onspira Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing life-changing drugs, bringing hope to patients with rare pulmonary diseases. The company’s leading candidate drug, OSP-101, is a novel compound currently under development for the treatment of bronchiolitis obliterans syndrome post lung transplantation.